News

Article

FDA approves the VISUMAX 800 with SMILE pro software for surgically treating nearsightedness

The VISUMAX 800 is the latest generation of Zeiss femtosecond lasers, and offers a reduced laser time when compared to its predecessors.

(Image Credit: AdobeStock/gustavofrazao)

(Image Credit: AdobeStock/gustavofrazao)

Zeiss Medical Technology announced the US Food and Drug Administration (FDA) has approved the VISUMAX 800 with SMILE pro software surgically treating nearsightedness, with or without astigmatism.

The VISUMAX 800 is the latest generation of Zeiss femtosecond lasers, and offers a reduced laser time when compared to its predecessors.1

According to press release from Zeiss,1 the VISUMAX 800 with SMILE pro software enables faster treatment by “creating the lenticule in less than 10 seconds thanks to a faster laser pulse repetition rate of 2 MHz,” while “a shorter suction time can increase peace of mind and reduce stress for you and your patients.”

With the VISUMAX 800 with SMILE pro software surgeons can “utilize a number of workflow enhancements including the CentraLign centration aid, a computer-controlled function for easy centration; the OcuLign cyclotorsion adjustment to help counter cyclotorsion that may occur; and VISULYZE user nomograms to help surgeons collect and analyze patient data, while also providing detailed nomograms and enabling more control during every surgery.”1

VISUMAX 800 with SMILE pro software from Zeiss. (Image courtesy Zeiss)

VISUMAX 800 with SMILE pro software from Zeiss. (Image courtesy Zeiss)

“The increasing global adoption of SMILE from Zeiss represents the positive impact the small incision lenticule extraction procedure continues to have on the quality of life for patients,” said Andrew Chang, Head of Global Sales for Zeiss Medical Technology. “With the availability of the Zeiss SMILE pro software module in the US market, surgeons can now offer the latest refractive technology to help expand their business and provide excellent outcomes for patients.”

Euan S Thomson, PhD, President of Ophthalmology Strategic Business Unit and Head of the Digital Business Unit for Zeiss Medical Technology, discussed the approval in the press release from the company.

“As part of the Zeiss Medical Ecosystem, this next-generation femtosecond laser system creates data-driven insights to help surgeons manage better treatment paths for patients while supporting each surgeon’s unique practice requirements for greater workflow efficiency and performance,” said Thomson.

References:
  1. U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS. Press release; January 11, 2024. Accessed January 11, 2024. https://www.zeiss.com/meditec-ag/en/media-news/press-releases/2024/fda-approves-visumax-800-with-smile-pro.html?utm_source=ln-organic&utm_medium=image-post&utm_campaign=fda-visumax-us&utm_term=press-release&utm_content=post-1

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
Image credit: Ophthalmology Times; EnVision Summit 2025: Sonia H. Yoo, MD, shares what to expect from the cataract and refractive agenda
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
EyeCon 2024: Adam Wenick, MD, talks about myopic interventions across the lifespan
© 2025 MJH Life Sciences

All rights reserved.